SCHEMBL287412

SCHEMBL287412

Cc1ccc(C(=O)CN2C=CCC(c3cc(Cc4ccccc4)[nH]n3)=C2)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
COMT P21964 4/20 0.41
HCAR2 Q8TDS4 1/20 0.37
ITK Q08881 6/20 0.35
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
DUSP3 P51452 1/20 0.33
PTPN5 P54829 1/20 0.33
PTPN11 Q06124 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
TACR3 P29371 1/20 0.33
CSNK2A2 P19784 1/20 0.33
KDR P35968 1/20 0.33
PLK1 P53350 1/20 0.33
CSNK2B P67870 1/20 0.33
CSNK2A1 P68400 1/20 0.33
PARP1 P09874 1/20 0.33
DRD2 P14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL287304 0.85 HCAR2 (0.43) COMTHCAR2ITKALDH1A1MAPT
SCHEMBL298106 0.82 RAB9A (0.31) ALDH1A1MAPT
SCHEMBL298638 0.81 LMNA (0.32) ALDH1A1HPGDKDR
SCHEMBL660037 0.80 NPC1 (0.36) ALDH1A1MAPTDUSP3PTPN5PTPN11
SCHEMBL286989 0.78 KDM5A (0.42) COMTHCAR2ITKDRD2DRD4
SCHEMBL287605 0.76 KMT2A (0.41) HCAR2ALDH1A1MAPTHPGDTSHR
SCHEMBL660695 0.75 HCAR2 (0.37) COMTHCAR2ITKALDH1A1HPGD
SCHEMBL660157 0.75 HTT (0.33) ALDH1A1MAPTDUSP3PTPN5PTPN11
SCHEMBL27854968 0.72 COMT (0.35) COMTHCAR2ITKCYP11B1CYP11B2
SCHEMBL27871671 0.72 HCAR2 (0.39) COMTHCAR2ITKALDH1A1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP claimed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US claimed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO claimed
EP-2427432-A2 NOVEL HETEROCYCLIC COMPOUNDS Torrent Pharmaceuticals Limited (IN) 2012-03-14 EP disclosed
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS DUTT CHAITANYA (IN) 2012-02-23 US disclosed
WO-2010128528-A2 NOVEL HETEROCYCLIC COMPOUNDS TORRENT PHARMACEUTICALS LIMITED (IN) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046317-A1 NOVEL HETEROCYCLIC COMPOUNDS AGER, REN, AGT COMT 2389/4885HCAR2 223/4885ITK 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.